Beam Therapeutics’ (BEAM) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM) in a report issued on Wednesday,Benzinga reports. They currently have a $65.00 price target on the stock.

BEAM has been the subject of a number of other reports. Sanford C. Bernstein reduced their price target on shares of Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Tudor Pickering set a $39.00 target price on Beam Therapeutics in a report on Wednesday, May 13th. Wall Street Zen upgraded Beam Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. Bank of America reaffirmed a “buy” rating and set a $47.00 price target on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Tuesday, August 25th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.00.

Beam Therapeutics Price Performance

Shares of BEAM opened at $23.99 on Wednesday. Beam Therapeutics has a one year low of $20.23 and a one year high of $38.26. The stock’s fifty day moving average is $28.50 and its 200-day moving average is $28.88. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.57 and a current ratio of 14.57. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -27.90 and a beta of 2.22.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $16.37 million. Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%.The business’s revenue for the quarter was down 94.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.00) EPS. Equities analysts anticipate that Beam Therapeutics will post -4.49 EPS for the current year.

Insider Activity at Beam Therapeutics

In other news, insider Fmr Llc sold 251,488 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the completion of the sale, the insider directly owned 854,583 shares of the company’s stock, valued at $30,132,596.58. This trade represents a 22.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Amy Simon sold 16,667 shares of the firm’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $25.74, for a total value of $429,008.58. Following the sale, the insider directly owned 85,696 shares of the company’s stock, valued at approximately $2,205,815.04. This represents a 16.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 301,527 shares of company stock worth $10,468,500. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Beam Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Alphabet Inc. acquired a new position in shares of Beam Therapeutics in the second quarter worth about $11,037,000. Canal Insurance CO purchased a new position in shares of Beam Therapeutics in the first quarter worth approximately $953,000. Ishara Investments LP purchased a new position in shares of Beam Therapeutics in the fourth quarter worth approximately $1,386,000. Janus Henderson Group PLC raised its holdings in shares of Beam Therapeutics by 136.1% during the first quarter. Janus Henderson Group PLC now owns 93,253 shares of the company’s stock valued at $2,222,000 after acquiring an additional 53,752 shares during the period. Finally, First Trust Advisors LP lifted its position in shares of Beam Therapeutics by 111.0% in the 1st quarter. First Trust Advisors LP now owns 135,166 shares of the company’s stock valued at $3,221,000 after acquiring an additional 71,110 shares in the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

Beam Therapeutics News Roundup

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Analysts maintain bullish views. Wedbush reaffirmed its Buy/Outperform rating, while Canaccord Genuity and JonesTrading also maintained Buy ratings. Separately, the brokerage consensus remains “Moderate Buy,” supporting investor confidence in Beam’s pipeline and long-term prospects. Wedbush Reaffirms Their Buy Rating Wedbush Reiterates Outperform Rating Consensus Moderate Buy Rating
• Positive Sentiment: BEAM-302 data show sustained biomarker improvement. Updated Phase 1/2 results in alpha-1 antitrypsin deficiency indicated that the investigational treatment restored AAT levels, with biomarker follow-up extending to 18 months. The results strengthen the case for continued development, although the study remains early stage and clinical benefit has not yet been conclusively established. BEAM-302 Clinical Data Analysis
• Neutral Sentiment: Options activity increased. Unusually large options trading was reported, which may signal heightened speculation or hedging but does not establish a clear directional outlook for BEAM. Unusually Large Options Trading
• Neutral Sentiment: Reports of a sharp increase in short interest showed zero shares both before and after the period, suggesting a data-quality issue rather than a meaningful change in bearish positioning.
• Negative Sentiment: Pomerantz LLP is investigating potential investor claims. The law firm’s announcement may add legal and headline risk, although it does not allege that Beam has been found liable. Pomerantz Investor Investigation

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source.

The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers.